At 4.1% CAGR, Europe Transdermal Drug Delivery System Market is Projected to be Worth US$ 14,422.86 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Europe transdermal drug delivery system market was valued at US$ 10,433.86 million in 2022 and is expected to reach US$ 14,422.86 million by 2030, registering a CAGR of 4.1% from 2022 to 2030. Increasing prevalence of chronic diseases and advancements in smart patches and 3D-printed patches by manufacturers are among the critical factors attributed to the Europe transdermal drug delivery system market expansion.

A transdermal drug administration route is novel and one of the reliable means of sustained drug delivery. With significant research being conducted in this field and the increasing interest of researchers in this form of drug delivery, a large number of transdermal patches are likely to reach the marketplace in the future. Transdermal patches are used to deliver drugs such as nicotine, fentanyl, nitroglycerin, and clonidine to treat various medical conditions. Recently, these patches have been explored to deliver biologics in various applications. Smart patches are equipped with sensors and other technologies to monitor patient conditions and adjust drug delivery accordingly. In January 2023, a lead scientist at Swansea University developed a new smart patch to detect proinflammatory biomarkers of neurodegenerative diseases such as Parkinson's and Alzheimer's using the microneedle technology. These smart patches comprise numerous microneedles designed to penetrate the skin barrier in a minimally invasive manner, followed by monitoring the biomarkers of clinical significance. They can be self-administered for point-of-care diagnosis at general practices or at home. This innovative research can potentially change the landscape of early neurodegenerative disease detection.

According to an article titled "3D-Printed Products for Topical Skin Applications: From Personalized Dressings to Drug Delivery," published in the National Library of Medicine in November 2021, personalized 3D-printed patches that conform to the skin surface can be used for acetyl-hexapeptide 3 (AHP-3) delivery. In this study, two liquid monomers-polyethylene glycol diacrylate (PEGDA) and vinylpyrrolidone (VP)-were used in different proportions to improve the mechanical strength, polymerization rate, and swelling rate of the final polymer. Optimal drug loading on the resin indicated that AHP-3 remained stable throughout the manufacturing process and had no effect on the physical properties of the final polymer. Using a 3D scanned facial model, a personalized patch was designed in computer-aided design software, and it was fabricated in optimized resin using a digital light processing 3D printer. The in-vitro characterization of prepared transdermal patches has shown their ability to penetrate human cadaver skin, further remaining intact upon compression. "3D-Printed Products for Topical Skin Applications: From Personalized Dressings to Drug Delivery" is the first study demonstrating personalized patches made using photopolymers, and it has introduced a novel approach to improve the transdermal delivery of drugs for effective wrinkle management.

Thus, the adoption of 3D printing technology and smart patches is likely to offer opportunities to the transdermal drug delivery systems market in the coming years.

On the contrary, adverse effects and recall of transdermal drug delivery systems hamper the growth of Europe transdermal drug delivery system market.

Based on type, the Europe transdermal drug delivery system market is categorized into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held 40.1% share of Europe transdermal drug delivery system market in 2022, amassing US$ 4,180.46 million. It is projected to garner US$ 5,892.60 million by 2030 to expand at 4.4% CAGR during 2022-2030. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.

In terms of application, the Europe transdermal drug delivery system market is segmented into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held 41.0% share of Europe transdermal drug delivery system market in 2022, amassing US$ 4,274.30 million. It is projected to garner US$ 5,903.35 million by 2030 to expand at 4.1% CAGR during 2022-2030. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.

By distribution channel, the Europe transdermal drug delivery system market is categorized into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held 43.0% share of Europe transdermal drug delivery system market in 2022, amassing US$ 4,489.78 million. It is projected to garner US$ 6,200.93 million by 2030 to expand at 4.1% CAGR during 2022-2030.

Based on country, the Europe transdermal drug delivery system market has been categorized into the UK, France, Germany, Spain, Italy, and the Rest of Europe. Our regional analysis states that Germany captured 21.0% share of Europe transdermal drug delivery system market in 2022. It was assessed at US$ 2,190.77 million in 2022 and is likely to hit US$ 3,203.15 million by 2030, exhibiting a CAGR of 4.9% during 2022-2030.

Key players operating in the Europe transdermal drug delivery system market are Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, UCB SA, and Viatris Inc, among others.

•    In August 2023, Novartis acquired Chinook Therapeutics Inc. Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront. The deal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin A receptor antagonist, and zigakibart, an anti-APRIL monoclonal antibody.
  
  
•    In September 2021, The purchase of Abexxa Biologics Inc. by Boehringer Ingelheim. Abexxa is a biopharmaceutical business that is pioneering immuno-oncology and oncology research to create the next generation of precision medicines that will transform the way cancer is treated. Through the acquisition, Boehringer Ingelheim have access to Abexxa's know-how in identifying cancer-specific proteins inside cells as opposed to those that are expressed on the cell membrane. As a result, there are more possible targets for cancer antigens. The technology of Abexxa in particular might result in the creation of cancer immunotherapies that are efficient in a wider variety of patients and cancer types.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com